Table 5.
Aspirin/Ibuprofen Use and the Risk of Colorectal Cancer in the PLCO Cancer Screening Trial
| NSAID use (times/month) |
Controls | Colorectal Cancer Overall | Proximal Colon | Distal Colon | Rectum | ||||
|---|---|---|---|---|---|---|---|---|---|
| Cases | HR (95% CI)* | Cases | HR (95% CI)* | Cases | HR (95% CI)* | Cases | HR (95% CI)* | ||
| Aspirin ^ | |||||||||
| <4 | 75905 | 1817 | 1.00 | 970 | 1.00 | 504 | 1.00 | 315 | 1.00 |
| 4 - <30 | 16084 | 309 | 0.79 (0.70, 0.89) | 169 | 0.80 (0.68, 0.94) | 78 | 0.73 (0.57, 0.93) | 57 | 0.86 (0.64, 1.14) |
| ≥30 | 32639 | 700 | 0.88 (0.81, 0.96) | 378 | 0.89 (0.79, 1.00) | 180 | 0.82 (0.69, 0.98) | 133 | 0.97 (0.79, 1.19) |
| P, trend | <0.0001 | 0.008 | 0.003 | 0.39 | |||||
| Ibuprofen ^ | |||||||||
| <4 | 101210 | 2375 | 1.00 | 1272 | 1.00 | 643 | 1.00 | 423 | 1.00 |
| 4 - <30 | 11432 | 231 | 0.92 (0.80, 1.05) | 133 | 0.98 (0.82, 1.18) | 57 | 0.84 (0.64, 1.11) | 40 | 0.88 (0.63, 1.23) |
| ≥30 | 11986 | 220 | 0.81 (0.70, 0.93) | 112 | 0.75 (0.62, 0.91) | 62 | 0.87 (0.66, 1.13) | 42 | 0.92 (0.67, 1.27) |
| P, trend | 0.003 | 0.0091 | 0.23 | 0.38 | |||||
| Combined use | |||||||||
| <4 | 61849 | 1545 | 1.00 | 824 | 1.00 | 422 | 1.00 | 275 | 1.00 |
| 4 - <30 | 22035 | 432 | 0.79 (0.71, 0.88) | 240 | 0.82 (0.71, 0.94) | 113 | 0.76 (0.62, 0.94) | 73 | 0.75 (0.58, 0.98) |
| 30 - <60 | 25437 | 550 | 0.85 (0.77, 0.94) | 293 | 0.84 (0.73, 0.96) | 145 | 0.84 (0.69, 1.02) | 105 | 0.91 (0.73, 1.15) |
| ≥60 | 15307 | 299 | 0.79 (0.69, 0.89) | 160 | 0.77 (0.65, 0.92) | 82 | 0.81 (0.64, 1.04) | 52 | 0.82 (0.60, 1.10) |
| P, trend | <0.0001 | 0.0003 | 0.02 | 0.15 | |||||
*
Hazard ratio (HR) and 95% confidence interval (CI) calculated by Cox proportional hazards regression adjusted for study center, race, sex, family history of colorectal cancer, smoking history, body mass index, trial arm, and calendar year at baseline (age was the underlying time metric)
^
Aspirin use is adjusted for Ibuprofen use and vice versa